Following price deals, Ibrance and Kisqali get green light from the NICE

16 November 2017

As a result of price deals with the manufacturers of breast cancer drugs palbociclib and ribociclib, they have received a green light for routine National Health Service (NHS) funding in England, says the National Institute for Health and Care Excellence.

Medicines cost-effectiveness watchdog the NICE has today published draft guidance recommending breast cancer drugs Ibrance (palbociclib) from US pharma giant Pfizer (NYSE: PFE) and Kisqali (ribociclib) from Swiss peer Novartis (NOVN: VX) for routine funding on the NHS.

Discounts to the price of both of these promising new drugs mean they can be recommended as options for people with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or secondary breast cancer, despite uncertainties about how long they extend overall survival.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK